APO Research
Talk to an analyst

APO RESEARCH · REPORT

Topoisomerase I Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Topoisomerase I Inhibitors Market Analysis and Forecast 2026-2032

21 December 2025200 pages

Choose your research edition.

Industry ResearchTopoisomerase I Inhibitors Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Topoisomerase I Inhibitors Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Topoisomerase I Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Topoisomerase I Inhibitors Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Topoisomerase I Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Topoisomerase I Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Topoisomerase I Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Topoisomerase I Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Topoisomerase I Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Topoisomerase I Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Topoisomerase I Inhibitors include Chong Kun Dang Pharmaceutical, Grand Pharmaceutical, Teva Pharmaceutical Industries, CSPC Pharmaceutical, Novartis AG, Kelun Pharmaceutical, Pfizer, Hengrui Pharmaceuticals and Daiichi Sankyo, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Topoisomerase I Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Topoisomerase I Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Topoisomerase I Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Topoisomerase I Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Topoisomerase I Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Topoisomerase I Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Topoisomerase I Inhibitors Segment by Company

Chong Kun Dang Pharmaceutical

Grand Pharmaceutical

Teva Pharmaceutical Industries

CSPC Pharmaceutical

Novartis AG

Kelun Pharmaceutical

Pfizer

Hengrui Pharmaceuticals

Daiichi Sankyo

Yakult Honsha

Summit Medical

Servier Laboratories (Aust)

Nippon Kayaku

MOH Holdings

Meitheal Pharmaceuticals

Les Laboratoires Servier SAS

Ipsen SA

Eton Pharmaceuticals

Topoisomerase I Inhibitors Segment by Type

Camptothecin Derivatives

Non-camptothecin

Topoisomerase I Inhibitors Segment by Application

Hospital

Clinic

Others

Topoisomerase I Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topoisomerase I Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Topoisomerase I Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topoisomerase I Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Topoisomerase I Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Topoisomerase I Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Topoisomerase I Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Topoisomerase I Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Camptothecin Derivatives Major Manufacturers Table 3. Non-camptothecin Major Manufacturers Table 4. Global Topoisomerase I Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Others Major Manufacturers Table 8. Topoisomerase I Inhibitors Industry Trends Table 9. Topoisomerase I Inhibitors Industry Drivers Table 10. Topoisomerase I Inhibitors Industry Opportunities and Challenges Table 11. Topoisomerase I Inhibitors Industry Restraints Table 12. Global Topoisomerase I Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Topoisomerase I Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Topoisomerase I Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2026) Table 16. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2027-2032) Table 17. Global Topoisomerase I Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Topoisomerase I Inhibitors Sales by Region (2021-2026) & (k units) Table 19. Global Topoisomerase I Inhibitors Sales by Region (2027-2032) & (k units) Table 20. Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2026) Table 21. Global Topoisomerase I Inhibitors Sales Market Share by Region (2027-2032) Table 22. Global Topoisomerase I Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Topoisomerase I Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Topoisomerase I Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Topoisomerase I Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 26. Global Topoisomerase I Inhibitors Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Topoisomerase I Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Topoisomerase I Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Topoisomerase I Inhibitors Manufacturers, Product Type & Application Table 30. Global Topoisomerase I Inhibitors Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Topoisomerase I Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Topoisomerase I Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2026) Table 37. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2027-2032) Table 38. Global Topoisomerase I Inhibitors Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 40. Global Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 41. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2026) Table 42. Global Topoisomerase I Inhibitors Sales Market Share by Type (2027-2032) Table 43. Global Topoisomerase I Inhibitors Price by Type (2021-2026) & (US$/unit) Table 44. Global Topoisomerase I Inhibitors Price by Type (2027-2032) & (US$/unit) Table 45. Global Topoisomerase I Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2026) Table 49. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2027-2032) Table 50. Global Topoisomerase I Inhibitors Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 52. Global Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 53. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2026) Table 54. Global Topoisomerase I Inhibitors Sales Market Share by Application (2027-2032) Table 55. Global Topoisomerase I Inhibitors Price by Application (2021-2026) & (US$/unit) Table 56. Global Topoisomerase I Inhibitors Price by Application (2027-2032) & (US$/unit) Table 57. Chong Kun Dang Pharmaceutical Company Information Table 58. Chong Kun Dang Pharmaceutical Business Overview Table 59. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 61. Chong Kun Dang Pharmaceutical Recent Development Table 62. Grand Pharmaceutical Company Information Table 63. Grand Pharmaceutical Business Overview Table 64. Grand Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 66. Grand Pharmaceutical Recent Development Table 67. Teva Pharmaceutical Industries Company Information Table 68. Teva Pharmaceutical Industries Business Overview Table 69. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio Table 71. Teva Pharmaceutical Industries Recent Development Table 72. CSPC Pharmaceutical Company Information Table 73. CSPC Pharmaceutical Business Overview Table 74. CSPC Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 76. CSPC Pharmaceutical Recent Development Table 77. Novartis AG Company Information Table 78. Novartis AG Business Overview Table 79. Novartis AG Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Novartis AG Topoisomerase I Inhibitors Product Portfolio Table 81. Novartis AG Recent Development Table 82. Kelun Pharmaceutical Company Information Table 83. Kelun Pharmaceutical Business Overview Table 84. Kelun Pharmaceutical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio Table 86. Kelun Pharmaceutical Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Pfizer Topoisomerase I Inhibitors Product Portfolio Table 91. Pfizer Recent Development Table 92. Hengrui Pharmaceuticals Company Information Table 93. Hengrui Pharmaceuticals Business Overview Table 94. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 96. Hengrui Pharmaceuticals Recent Development Table 97. Daiichi Sankyo Company Information Table 98. Daiichi Sankyo Business Overview Table 99. Daiichi Sankyo Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio Table 101. Daiichi Sankyo Recent Development Table 102. Yakult Honsha Company Information Table 103. Yakult Honsha Business Overview Table 104. Yakult Honsha Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Yakult Honsha Topoisomerase I Inhibitors Product Portfolio Table 106. Yakult Honsha Recent Development Table 107. Summit Medical Company Information Table 108. Summit Medical Business Overview Table 109. Summit Medical Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Summit Medical Topoisomerase I Inhibitors Product Portfolio Table 111. Summit Medical Recent Development Table 112. Servier Laboratories (Aust) Company Information Table 113. Servier Laboratories (Aust) Business Overview Table 114. Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio Table 116. Servier Laboratories (Aust) Recent Development Table 117. Nippon Kayaku Company Information Table 118. Nippon Kayaku Business Overview Table 119. Nippon Kayaku Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio Table 121. Nippon Kayaku Recent Development Table 122. MOH Holdings Company Information Table 123. MOH Holdings Business Overview Table 124. MOH Holdings Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. MOH Holdings Topoisomerase I Inhibitors Product Portfolio Table 126. MOH Holdings Recent Development Table 127. Meitheal Pharmaceuticals Company Information Table 128. Meitheal Pharmaceuticals Business Overview Table 129. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 131. Meitheal Pharmaceuticals Recent Development Table 132. Les Laboratoires Servier SAS Company Information Table 133. Les Laboratoires Servier SAS Business Overview Table 134. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio Table 136. Les Laboratoires Servier SAS Recent Development Table 137. Ipsen SA Company Information Table 138. Ipsen SA Business Overview Table 139. Ipsen SA Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. Ipsen SA Topoisomerase I Inhibitors Product Portfolio Table 141. Ipsen SA Recent Development Table 142. Eton Pharmaceuticals Company Information Table 143. Eton Pharmaceuticals Business Overview Table 144. Eton Pharmaceuticals Topoisomerase I Inhibitors Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 145. Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio Table 146. Eton Pharmaceuticals Recent Development Table 147. North America Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 148. North America Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 149. North America Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 150. North America Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 151. North America Topoisomerase I Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 152. North America Topoisomerase I Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 153. North America Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 156. North America Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 157. North America Topoisomerase I Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 158. North America Topoisomerase I Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 159. North America Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. North America Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. North America Topoisomerase I Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. North America Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 163. North America Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 164. North America Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 165. North America Topoisomerase I Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 166. North America Topoisomerase I Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 167. United States Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 168. Canada Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 169. Mexico Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 170. Europe Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 173. Europe Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 174. Europe Topoisomerase I Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 175. Europe Topoisomerase I Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 176. Europe Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 177. Europe Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 178. Europe Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 179. Europe Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 180. Europe Topoisomerase I Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 181. Europe Topoisomerase I Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 182. Europe Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Europe Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Europe Topoisomerase I Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Europe Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 186. Europe Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 187. Europe Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 188. Europe Topoisomerase I Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 189. Europe Topoisomerase I Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 190. Germany Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 191. France Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 192. U.K. Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 193. Italy Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 194. Russia Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 195. Spain Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 197. Switzerland Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 198. Sweden Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 199. Poland Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 200. China Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 201. China Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 202. China Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 203. China Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 204. China Topoisomerase I Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 205. China Topoisomerase I Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 206. China Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 207. China Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 208. China Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 209. China Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 210. China Topoisomerase I Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 211. China Topoisomerase I Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 212. Asia Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 213. Asia Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 214. Asia Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 215. Asia Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 216. Asia Topoisomerase I Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 217. Asia Topoisomerase I Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 218. Asia Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 219. Asia Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 220. Asia Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 221. Asia Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 222. Asia Topoisomerase I Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 223. Asia Topoisomerase I Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 224. Asia Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. Asia Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. Asia Topoisomerase I Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. Asia Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 228. Asia Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 229. Asia Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 230. Asia Topoisomerase I Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 231. Asia Topoisomerase I Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 232. Japan Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 233. South Korea Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 234. India Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 235. Australia Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 236. Taiwan Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 237. Southeast Asia Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 238. SAMEA Topoisomerase I Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 239. SAMEA Topoisomerase I Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 240. SAMEA Topoisomerase I Inhibitors Sales by Type (2021-2026) & (k units) Table 241. SAMEA Topoisomerase I Inhibitors Sales by Type (2027-2032) & (k units) Table 242. SAMEA Topoisomerase I Inhibitors Sales Price by Type (2021-2026) & (US$/unit) Table 243. SAMEA Topoisomerase I Inhibitors Sales Price by Type (2027-2032) & (US$/unit) Table 244. SAMEA Topoisomerase I Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 245. SAMEA Topoisomerase I Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 246. SAMEA Topoisomerase I Inhibitors Sales by Application (2021-2026) & (k units) Table 247. SAMEA Topoisomerase I Inhibitors Sales by Application (2027-2032) & (k units) Table 248. SAMEA Topoisomerase I Inhibitors Sales Price by Application (2021-2026) & (US$/unit) Table 249. SAMEA Topoisomerase I Inhibitors Sales Price by Application (2027-2032) & (US$/unit) Table 250. SAMEA Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 251. SAMEA Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 252. SAMEA Topoisomerase I Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 253. SAMEA Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 254. SAMEA Topoisomerase I Inhibitors Sales by Country (2021-2026) & (k units) Table 255. SAMEA Topoisomerase I Inhibitors Sales by Country (2027-2032) & (k units) Table 256. SAMEA Topoisomerase I Inhibitors Sales Price by Country (2021-2026) & (US$/unit) Table 257. SAMEA Topoisomerase I Inhibitors Sales Price by Country (2027-2032) & (US$/unit) Table 258. Brazil Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 259. Argentina Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 260. Chile Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 261. Colombia Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 262. Peru Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 263. Saudi Arabia Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 264. Israel Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 265. UAE Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 266. Turkey Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 267. Iran Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 268. Egypt Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Table 269. Key Raw Materials Table 270. Raw Materials Key Suppliers Table 271. Topoisomerase I Inhibitors Distributors List Table 272. Topoisomerase I Inhibitors Customers List Table 273. Research Programs/Design for This Report Table 274. Authors List of This Report Table 275. Secondary Sources Table 276. Primary Sources List of Figures Figure 1. Topoisomerase I Inhibitors Image Figure 2. Global Topoisomerase I Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Topoisomerase I Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Camptothecin Derivatives Image Figure 5. Non-camptothecin Image Figure 6. Global Topoisomerase I Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Topoisomerase I Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Topoisomerase I Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Topoisomerase I Inhibitors Revenue (2021-2032) & (US$ Million) Figure 13. Global Topoisomerase I Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Topoisomerase I Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2032) Figure 16. Global Topoisomerase I Inhibitors Sales (2021-2032) & (k units) Figure 17. Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Topoisomerase I Inhibitors Sales YoY (2021-2032) & (k units) Figure 20. Europe Topoisomerase I Inhibitors Sales YoY (2021-2032) & (k units) Figure 21. China Topoisomerase I Inhibitors Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Topoisomerase I Inhibitors Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Topoisomerase I Inhibitors Sales YoY (2021-2032) & (k units) Figure 24. Global Topoisomerase I Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Topoisomerase I Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Topoisomerase I Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Topoisomerase I Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032) Figure 30. Global Topoisomerase I Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Topoisomerase I Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032) Figure 33. Global Topoisomerase I Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Topoisomerase I Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032) Figure 36. Global Topoisomerase I Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Topoisomerase I Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032) Figure 39. North America Topoisomerase I Inhibitors Revenue Share by Type (2021-2032) Figure 40. North America Topoisomerase I Inhibitors Sales Share by Type (2021-2032) Figure 41. North America Topoisomerase I Inhibitors Revenue Share by Application (2021-2032) Figure 42. North America Topoisomerase I Inhibitors Sales Share by Application (2021-2032) Figure 43. North America Topoisomerase I Inhibitors Revenue Share by Country (2021-2032) Figure 44. North America Topoisomerase I Inhibitors Sales Share by Country (2021-2032) Figure 45. Europe Topoisomerase I Inhibitors Revenue Share by Type (2021-2032) Figure 46. Europe Topoisomerase I Inhibitors Sales Share by Type (2021-2032) Figure 47. Europe Topoisomerase I Inhibitors Revenue Share by Application (2021-2032) Figure 48. Europe Topoisomerase I Inhibitors Sales Share by Application (2021-2032) Figure 49. Europe Topoisomerase I Inhibitors Revenue Share by Country (2021-2032) Figure 50. Europe Topoisomerase I Inhibitors Sales Share by Country (2021-2032) Figure 51. China Topoisomerase I Inhibitors Revenue Share by Type (2021-2032) Figure 52. China Topoisomerase I Inhibitors Sales Share by Type (2021-2032) Figure 53. China Topoisomerase I Inhibitors Revenue Share by Application (2021-2032) Figure 54. China Topoisomerase I Inhibitors Sales Share by Application (2021-2032) Figure 55. Asia Topoisomerase I Inhibitors Revenue Share by Type (2021-2032) Figure 56. Asia Topoisomerase I Inhibitors Sales Share by Type (2021-2032) Figure 57. Asia Topoisomerase I Inhibitors Revenue Share by Application (2021-2032) Figure 58. Asia Topoisomerase I Inhibitors Sales Share by Application (2021-2032) Figure 59. Asia Topoisomerase I Inhibitors Revenue Share by Country (2021-2032) Figure 60. Asia Topoisomerase I Inhibitors Sales Share by Country (2021-2032) Figure 61. SAMEA Topoisomerase I Inhibitors Revenue Share by Type (2021-2032) Figure 62. SAMEA Topoisomerase I Inhibitors Sales Share by Type (2021-2032) Figure 63. SAMEA Topoisomerase I Inhibitors Revenue Share by Application (2021-2032) Figure 64. SAMEA Topoisomerase I Inhibitors Sales Share by Application (2021-2032) Figure 65. SAMEA Topoisomerase I Inhibitors Revenue Share by Country (2021-2032) Figure 66. SAMEA Topoisomerase I Inhibitors Sales Share by Country (2021-2032) Figure 67. Topoisomerase I Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Topoisomerase I Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Camptothecin Derivatives
  • Non-camptothecin
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chong Kun Dang Pharmaceutical
  • Grand Pharmaceutical
  • Teva Pharmaceutical Industries
  • CSPC Pharmaceutical
  • Novartis AG
  • Kelun Pharmaceutical
  • Pfizer
  • Hengrui Pharmaceuticals
  • Daiichi Sankyo
  • Yakult Honsha
  • Summit Medical
  • Servier Laboratories (Aust)
  • Nippon Kayaku
  • MOH Holdings
  • Meitheal Pharmaceuticals
  • Les Laboratoires Servier SAS
  • Ipsen SA
  • Eton Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Topoisomerase I Inhibitors Market by Type
  3. 1.2.1 Global Topoisomerase I Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Camptothecin Derivatives
  5. 1.2.3 Non-camptothecin
  6. 1.3 Topoisomerase I Inhibitors Market by Application
  7. 1.3.1 Global Topoisomerase I Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Topoisomerase I Inhibitors Market Dynamics
  1. 2.1 Topoisomerase I Inhibitors Industry Trends
  2. 2.2 Topoisomerase I Inhibitors Industry Drivers
  3. 2.3 Topoisomerase I Inhibitors Industry Opportunities and Challenges
  4. 2.4 Topoisomerase I Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Topoisomerase I Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Topoisomerase I Inhibitors Revenue by Region
  3. 3.2.1 Global Topoisomerase I Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Topoisomerase I Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global Topoisomerase I Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global Topoisomerase I Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Topoisomerase I Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Topoisomerase I Inhibitors Sales by Region
  9. 3.4.1 Global Topoisomerase I Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Topoisomerase I Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global Topoisomerase I Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global Topoisomerase I Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Topoisomerase I Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global Topoisomerase I Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Topoisomerase I Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Topoisomerase I Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Topoisomerase I Inhibitors Sales by Manufacturers
  6. 4.2.1 Global Topoisomerase I Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Topoisomerase I Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Topoisomerase I Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Topoisomerase I Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Topoisomerase I Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Topoisomerase I Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Topoisomerase I Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global Topoisomerase I Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Topoisomerase I Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 Topoisomerase I Inhibitors Tier 1, Tier 2, and Tier 3
5 Topoisomerase I Inhibitors Market by Type
  1. 5.1 Global Topoisomerase I Inhibitors Revenue by Type
  2. 5.1.1 Global Topoisomerase I Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Topoisomerase I Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Topoisomerase I Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Topoisomerase I Inhibitors Sales by Type
  6. 5.2.1 Global Topoisomerase I Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Topoisomerase I Inhibitors Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Topoisomerase I Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Topoisomerase I Inhibitors Price by Type
6 Topoisomerase I Inhibitors Market by Application
  1. 6.1 Global Topoisomerase I Inhibitors Revenue by Application
  2. 6.1.1 Global Topoisomerase I Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Topoisomerase I Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Topoisomerase I Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Topoisomerase I Inhibitors Sales by Application
  6. 6.2.1 Global Topoisomerase I Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Topoisomerase I Inhibitors Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Topoisomerase I Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Topoisomerase I Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Chong Kun Dang Pharmaceutical
  2. 7.1.1 Chong Kun Dang Pharmaceutical Company Information
  3. 7.1.2 Chong Kun Dang Pharmaceutical Business Overview
  4. 7.1.3 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chong Kun Dang Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  6. 7.1.5 Chong Kun Dang Pharmaceutical Recent Developments
  7. 7.2 Grand Pharmaceutical
  8. 7.2.1 Grand Pharmaceutical Company Information
  9. 7.2.2 Grand Pharmaceutical Business Overview
  10. 7.2.3 Grand Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Grand Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  12. 7.2.5 Grand Pharmaceutical Recent Developments
  13. 7.3 Teva Pharmaceutical Industries
  14. 7.3.1 Teva Pharmaceutical Industries Company Information
  15. 7.3.2 Teva Pharmaceutical Industries Business Overview
  16. 7.3.3 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Teva Pharmaceutical Industries Topoisomerase I Inhibitors Product Portfolio
  18. 7.3.5 Teva Pharmaceutical Industries Recent Developments
  19. 7.4 CSPC Pharmaceutical
  20. 7.4.1 CSPC Pharmaceutical Company Information
  21. 7.4.2 CSPC Pharmaceutical Business Overview
  22. 7.4.3 CSPC Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 CSPC Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  24. 7.4.5 CSPC Pharmaceutical Recent Developments
  25. 7.5 Novartis AG
  26. 7.5.1 Novartis AG Company Information
  27. 7.5.2 Novartis AG Business Overview
  28. 7.5.3 Novartis AG Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis AG Topoisomerase I Inhibitors Product Portfolio
  30. 7.5.5 Novartis AG Recent Developments
  31. 7.6 Kelun Pharmaceutical
  32. 7.6.1 Kelun Pharmaceutical Company Information
  33. 7.6.2 Kelun Pharmaceutical Business Overview
  34. 7.6.3 Kelun Pharmaceutical Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kelun Pharmaceutical Topoisomerase I Inhibitors Product Portfolio
  36. 7.6.5 Kelun Pharmaceutical Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Topoisomerase I Inhibitors Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Hengrui Pharmaceuticals
  44. 7.8.1 Hengrui Pharmaceuticals Company Information
  45. 7.8.2 Hengrui Pharmaceuticals Business Overview
  46. 7.8.3 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hengrui Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  48. 7.8.5 Hengrui Pharmaceuticals Recent Developments
  49. 7.9 Daiichi Sankyo
  50. 7.9.1 Daiichi Sankyo Company Information
  51. 7.9.2 Daiichi Sankyo Business Overview
  52. 7.9.3 Daiichi Sankyo Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Daiichi Sankyo Topoisomerase I Inhibitors Product Portfolio
  54. 7.9.5 Daiichi Sankyo Recent Developments
  55. 7.10 Yakult Honsha
  56. 7.10.1 Yakult Honsha Company Information
  57. 7.10.2 Yakult Honsha Business Overview
  58. 7.10.3 Yakult Honsha Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Yakult Honsha Topoisomerase I Inhibitors Product Portfolio
  60. 7.10.5 Yakult Honsha Recent Developments
  61. 7.11 Summit Medical
  62. 7.11.1 Summit Medical Company Information
  63. 7.11.2 Summit Medical Business Overview
  64. 7.11.3 Summit Medical Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Summit Medical Topoisomerase I Inhibitors Product Portfolio
  66. 7.11.5 Summit Medical Recent Developments
  67. 7.12 Servier Laboratories (Aust)
  68. 7.12.1 Servier Laboratories (Aust) Company Information
  69. 7.12.2 Servier Laboratories (Aust) Business Overview
  70. 7.12.3 Servier Laboratories (Aust) Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Servier Laboratories (Aust) Topoisomerase I Inhibitors Product Portfolio
  72. 7.12.5 Servier Laboratories (Aust) Recent Developments
  73. 7.13 Nippon Kayaku
  74. 7.13.1 Nippon Kayaku Company Information
  75. 7.13.2 Nippon Kayaku Business Overview
  76. 7.13.3 Nippon Kayaku Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Nippon Kayaku Topoisomerase I Inhibitors Product Portfolio
  78. 7.13.5 Nippon Kayaku Recent Developments
  79. 7.14 MOH Holdings
  80. 7.14.1 MOH Holdings Company Information
  81. 7.14.2 MOH Holdings Business Overview
  82. 7.14.3 MOH Holdings Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 MOH Holdings Topoisomerase I Inhibitors Product Portfolio
  84. 7.14.5 MOH Holdings Recent Developments
  85. 7.15 Meitheal Pharmaceuticals
  86. 7.15.1 Meitheal Pharmaceuticals Company Information
  87. 7.15.2 Meitheal Pharmaceuticals Business Overview
  88. 7.15.3 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Meitheal Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  90. 7.15.5 Meitheal Pharmaceuticals Recent Developments
  91. 7.16 Les Laboratoires Servier SAS
  92. 7.16.1 Les Laboratoires Servier SAS Company Information
  93. 7.16.2 Les Laboratoires Servier SAS Business Overview
  94. 7.16.3 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Les Laboratoires Servier SAS Topoisomerase I Inhibitors Product Portfolio
  96. 7.16.5 Les Laboratoires Servier SAS Recent Developments
  97. 7.17 Ipsen SA
  98. 7.17.1 Ipsen SA Company Information
  99. 7.17.2 Ipsen SA Business Overview
  100. 7.17.3 Ipsen SA Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Ipsen SA Topoisomerase I Inhibitors Product Portfolio
  102. 7.17.5 Ipsen SA Recent Developments
  103. 7.18 Eton Pharmaceuticals
  104. 7.18.1 Eton Pharmaceuticals Company Information
  105. 7.18.2 Eton Pharmaceuticals Business Overview
  106. 7.18.3 Eton Pharmaceuticals Topoisomerase I Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Eton Pharmaceuticals Topoisomerase I Inhibitors Product Portfolio
  108. 7.18.5 Eton Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Topoisomerase I Inhibitors Market Size by Type
  2. 8.1.1 North America Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America Topoisomerase I Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America Topoisomerase I Inhibitors Price by Type (2021-2032)
  5. 8.2 North America Topoisomerase I Inhibitors Market Size by Application
  6. 8.2.1 North America Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America Topoisomerase I Inhibitors Price by Application (2021-2032)
  9. 8.3 North America Topoisomerase I Inhibitors Market Size by Country
  10. 8.3.1 North America Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Topoisomerase I Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Topoisomerase I Inhibitors Market Size by Type
  2. 9.1.1 Europe Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Topoisomerase I Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe Topoisomerase I Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe Topoisomerase I Inhibitors Market Size by Application
  6. 9.2.1 Europe Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe Topoisomerase I Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe Topoisomerase I Inhibitors Market Size by Country
  10. 9.3.1 Europe Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Topoisomerase I Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Topoisomerase I Inhibitors Market Size by Type
  2. 10.1.1 China Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China Topoisomerase I Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China Topoisomerase I Inhibitors Price by Type (2021-2032)
  5. 10.2 China Topoisomerase I Inhibitors Market Size by Application
  6. 10.2.1 China Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China Topoisomerase I Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Topoisomerase I Inhibitors Market Size by Type
  2. 11.1.1 Asia Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Topoisomerase I Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia Topoisomerase I Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia Topoisomerase I Inhibitors Market Size by Application
  6. 11.2.1 Asia Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia Topoisomerase I Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia Topoisomerase I Inhibitors Market Size by Country
  10. 11.3.1 Asia Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Topoisomerase I Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Topoisomerase I Inhibitors Market Size by Type
  2. 12.1.1 SAMEA Topoisomerase I Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Topoisomerase I Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Topoisomerase I Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA Topoisomerase I Inhibitors Market Size by Application
  6. 12.2.1 SAMEA Topoisomerase I Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Topoisomerase I Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Topoisomerase I Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA Topoisomerase I Inhibitors Market Size by Country
  10. 12.3.1 SAMEA Topoisomerase I Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Topoisomerase I Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Topoisomerase I Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Topoisomerase I Inhibitors Value Chain Analysis
  2. 13.1.1 Topoisomerase I Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Topoisomerase I Inhibitors Production Mode & Process
  6. 13.2 Topoisomerase I Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Topoisomerase I Inhibitors Distributors
  9. 13.2.3 Topoisomerase I Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst